Genomewide NIPT screening allows not only for the detection of common chromosomal aneuploidies but provides a comprehensive view of all 23 chromosome pairs. It enables the identification of rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs) as well as partial deletions and duplications (also referred to as copy number variations CNVs) that are ≥7 Mb in size.
These additional chromosomal abnormalities have been associated with clinically relevant outcomes such as developmental delays, intellectual disabilities, structural anomalies and adverse pregnancy outcomes.
Having insight into these chromosomal abnormalities earlier may assist you and your patient in the management of the pregnancy.
The American Congress of Obstetricians and Gynaecologists (ACOG) and International Society of Prenatal Diagnosis (ISPD), along with other professional societies, have stated that NIPT is an available screening option for all pregnant women1,8.
Anyone considering genomewide testing is strongly advised to have an appointment with a genetic counsellor / detailed discussion with their obstetrician (regardless of the indication).
T21 (Down syndrome), T18 (Edward syndrome), T13 (Patau syndrome)
Provides chromosomal status for all chromosomes and segmental deletions and duplications >7Mb.
Information on the status of fetal sex chromosomes and certain sex chromosome aneuploidies.
22q11 deletion (Di George), 15q11 deletion (Angelman/Prader-Willi), 1p36 deletion, 4p (Wolf-Hirschhorn) 5p (Cri-du-chat)
*Please note that Microdeletion samples are currently sent to the United States.
Screening of cell-free DNA for common chromosomal conditions, from 10 weeks of gestational age.
Chromosome 21 (T21)
Chromosome 21, 18, 13, X&Y
Chromosome 21, 18, 13, X&Y & Microdeletions*
All Chromosome & Microdeletions*
*Microdeletions includes the following syndromes: 22q11 deletion (DiGoerge), 15q11 deletion (Angelman/Prader-Willi), 1p36 deletion, 4p- (Wolf-Hirschhorn), 5p- (Cri-di-chat)
*Please note that all prices include VAT and are subject to change.
Powered by Illumina, global leader in next generation sequencing.
Next Biosciences has been offering the Illumina NIPT test in South Africa since 2016.
In-house processing ensuring a quicker turnaround time.
VeriSeqTM NIPT Solution V2, providing the most comprehensive view of genomewide fetal chromosomal anomalies.
1.2% Failure rate (resulting in less re-draws than other tests).
A high accuracy with low fetal fraction - No fetal fraction cut-off (relies on a dynamic threshold (iFact), which reduces NIPT failures).
Access to specialist team of Genetic Scientists, a Medical Doctor, Pathologist and Genetic Counsellor.
One free genetic counselling session for all high risk results, providing your patients with the support they need.
Dedicated client service team to support both you and your patients.
Test failure rates are substantially lower with whole genome sequencing versus other methodologies4, 7-9.
With its high levels of sensitivity and accuracy, NGS produces the data quality needed for reliable analysis of the trace amounts of cfDNA found circulating within blood plasma.
Disclaimer:Non-Invasive Prenatal Testing (NIPT) based on cell-free DNA analysis from maternal blood is a screening test; it is not diagnostic. Test results must not be used as the sole basis for diagnosis. Further confirmatory testing is necessary prior to making any irreversible pregnancy decision.